AK

Anirudhan Kadamkuni

Active Director Director DIN 08318686
DIN 08318686 First appointment Jan 2019 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2019
Shareholding value β€’β€’β€’β€’ Premium profile

About Anirudhan Kadamkuni

Data last updated:

Anirudhan Kadamkuni is a Director at Agueda Pharmaceuticals Private Limited (since 2019). The company operates in Business Services.

DIN 08318686
Primary Designation Director
Industry Business Services
First Appointment 03 Jan 2019
Oldest Company Age 9 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 Jan 20192017Active

Directorship timeline

Open interactive timeline →
Agueda Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Anirudhan Kadamkuni

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anirudhan Kadamkuni

Anirudhan Kadamkuni currently holds 1 directorship: Agueda Pharmaceuticals Private Limited (Director, since 03 Jan 2019).

Anirudhan Kadamkuni was first appointed on 03 Jan 2019 as Director at Agueda Pharmaceuticals Private Limited.

The current boards of Anirudhan Kadamkuni's companies include Ganesh Babu Kizhake Veetil (Agueda Pharmaceuticals Private Limited), Jayan Karthanam Veedu (Agueda Pharmaceuticals Private Limited), Nasar Kuchanath House (Agueda Pharmaceuticals Private Limited), Sreevidya Poyil Narayanan (Agueda Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available